108 related articles for article (PubMed ID: 38728375)
1. How I Use Next Generation Sequencing-MRD to Plan Approach and Prevent Relapse after HCT for Children and Adults with ALL.
Muffly L; Liang EC; Dolan JG; Pulsipher MA
Blood; 2024 May; ():. PubMed ID: 38728375
[TBL] [Abstract][Full Text] [Related]
2. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
[TBL] [Abstract][Full Text] [Related]
3. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.
Pulsipher MA; Carlson C; Langholz B; Wall DA; Schultz KR; Bunin N; Kirsch I; Gastier-Foster JM; Borowitz M; Desmarais C; Williamson D; Kalos M; Grupp SA
Blood; 2015 May; 125(22):3501-8. PubMed ID: 25862561
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation.
Liang EC; Dekker SE; Sabile JMG; Torelli S; Zhang A; Miller K; Shiraz P; Hayes-Lattin B; Leonard JT; Muffly L
Blood Adv; 2023 Jul; 7(14):3395-3402. PubMed ID: 37196642
[TBL] [Abstract][Full Text] [Related]
5. Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes From a Single-Center Study.
Ashouri K; Nittur V; Ginosyan AA; Hwang J; Adnani B; Chen D; Savitala-Damerla L; Schiff K; Chaudhary P; Kovach AE; Ladha A; Siddiqi I; Ali A; Woan K; Tam E; Yaghmour G
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e59-e66.e2. PubMed ID: 38061959
[TBL] [Abstract][Full Text] [Related]
6. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
[TBL] [Abstract][Full Text] [Related]
7. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT.
Nagler A; Baron F; Labopin M; Polge E; Esteve J; Bazarbachi A; Brissot E; Bug G; Ciceri F; Giebel S; Gilleece MH; Gorin NC; Lanza F; Peric Z; Ruggeri A; Sanz J; Savani BN; Schmid C; Shouval R; Spyridonidis A; Versluis J; Mohty M
Bone Marrow Transplant; 2021 Jan; 56(1):218-224. PubMed ID: 32724200
[TBL] [Abstract][Full Text] [Related]
8. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse.
Short NJ; Kantarjian H; Ravandi F; Konopleva M; Jain N; Kanagal-Shamanna R; Patel KP; Macaron W; Kadia TM; Wang S; Jorgensen JL; Khoury JD; Yilmaz M; Kebriaei P; Takahashi K; Garcia-Manero G; Daver N; Post SM; Huang X; Kornblau SM; Pelletier S; Flores W; Matthews J; Garris R; Jabbour E
Blood Adv; 2022 Jul; 6(13):4006-4014. PubMed ID: 35533262
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
[TBL] [Abstract][Full Text] [Related]
10. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
11. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
Zhou Y; Othus M; Araki D; Wood BL; Radich JP; Halpern AB; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
Leukemia; 2016 Jul; 30(7):1456-64. PubMed ID: 27012865
[TBL] [Abstract][Full Text] [Related]
12. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
Logan AC; Vashi N; Faham M; Carlton V; Kong K; Buño I; Zheng J; Moorhead M; Klinger M; Zhang B; Waqar A; Zehnder JL; Miklos DB
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1307-13. PubMed ID: 24769317
[TBL] [Abstract][Full Text] [Related]
14. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
[TBL] [Abstract][Full Text] [Related]
15. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
16. Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.
Muffly L; Sundaram V; Chen C; Yurkiewicz I; Kuo E; Burnash S; Spiegel JY; Arai S; Frank MJ; Johnston LJ; Lowsky R; Meyer EH; Negrin RS; Rezvani AR; Sidana S; Shiraz P; Shizuru JA; Weng WK; Liedtke M; Vempaty HT; Miklos DB
Blood Adv; 2021 Aug; 5(16):3147-3151. PubMed ID: 34424318
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing.
Oliva S; Genuardi E; Paris L; D'Agostino M; Rogers J; Rota-Scalabrini D; Jacob AP; Patriarca F; Luppi M; Bertazzoni P; Velluti C; Capra A; Saraci E; Rossi M; Allegra A; Mina R; Gentile M; Kirsch IR; Belotti A; Cavo M; Bruno B; Musto P; Boccadoro M; Zamagni E; Gay F
EClinicalMedicine; 2023 Jun; 60():102016. PubMed ID: 37396800
[TBL] [Abstract][Full Text] [Related]
18. Measurable residual disease of acute lymphoblastic leukemia in allograft settings: how to evaluate and intervene.
Sun YQ; Li SQ; Zhao XS; Chang YJ
Expert Rev Anticancer Ther; 2020 Jun; 20(6):453-464. PubMed ID: 32459519
[TBL] [Abstract][Full Text] [Related]
19. Advances in hematopoietic cell transplant for the treatment of hematologic malignancies.
Taraseviciute A; Pulsipher MA
Curr Opin Pediatr; 2019 Feb; 31(1):3-13. PubMed ID: 30585866
[TBL] [Abstract][Full Text] [Related]
20. Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission.
Klyuchnikov E; Badbaran A; Massoud R; Fritzsche-Friedland U; Freiberger P; Ayuk F; Wolschke C; Bacher U; Kröger N
Transplant Cell Ther; 2022 Jul; 28(7):374.e1-374.e9. PubMed ID: 35429661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
